Puma Biotechnology 대차 대조표 상태
재무 상태 기준 확인 5/6
Puma Biotechnology has a total shareholder equity of $48.5M and total debt of $89.1M, which brings its debt-to-equity ratio to 183.6%. Its total assets and total liabilities are $205.0M and $156.5M respectively. Puma Biotechnology's EBIT is $19.5M making its interest coverage ratio 2. It has cash and short-term investments of $96.8M.
주요 정보
183.6%
부채 비율
US$89.06m
부채
| 이자 보상 비율 | 2x |
| 현금 | US$96.83m |
| 주식 | US$48.51m |
| 총 부채 | US$156.49m |
| 총 자산 | US$205.00m |
최근 재무 상태 업데이트
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Recent updates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04재무 상태 분석
단기부채: PBYI's short term assets ($137.7M) exceed its short term liabilities ($104.3M).
장기 부채: PBYI's short term assets ($137.7M) exceed its long term liabilities ($52.2M).
부채 대 자본 내역 및 분석
부채 수준: PBYI has more cash than its total debt.
부채 감소: PBYI's debt to equity ratio has reduced from 429.2% to 183.6% over the past 5 years.
부채 범위: PBYI's debt is well covered by operating cash flow (37.4%).
이자 보장: PBYI's interest payments on its debt are not well covered by EBIT (2x coverage).